Proprietary AI analyst is now available

New Horizon Health Valuation Multiples

Discover revenue and EBITDA valuation multiples for New Horizon Health and similar public comparables like Novogene, Castle Biosciences, Genfit, Azenta and more.

New Horizon Health Overview

About New Horizon Health

New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.


Founded

2018

HQ

China

Employees

878

Financials (FY)

Revenue: $113M
EBITDA: ($7M)

EV

$816M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

New Horizon Health Financials

New Horizon Health reported last fiscal year revenue of $113M and negative EBITDA of ($7M).

In the same fiscal year, New Horizon Health generated $95M in gross profit, ($7M) in EBITDA losses, and had net loss of ($12M).


New Horizon Health P&L

In the most recent fiscal year, New Horizon Health reported revenue of $113M and EBITDA of ($7M).

New Horizon Health is unprofitable as of last fiscal year, with gross margin of 84%, EBITDA margin of (6%), and net margin of (10%).

See analyst estimates for New Horizon Health
Last FY202620272028
Revenue$113M
Gross Profit$95M
Gross Margin84%
EBITDA($7M)
EBITDA Margin(6%)
EBIT Margin(21%)
Net Profit($12M)
Net Margin(10%)

Financial data powered by Morningstar, Inc.

New Horizon Health Stock Performance

New Horizon Health has current market cap of $816M, and enterprise value of $816M.


New Horizon Health's stock price is $3.64.

New Horizon Health has an EPS (earnings per share) of $-0.05.

See more trading valuation data for New Horizon Health
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$816M$816M0.0%---$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

New Horizon Health Valuation Multiples

New Horizon Health trades at 7.2x EV/Revenue multiple, and (120.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for New Horizon Health

New Horizon Health Financial Valuation Multiples

As of June 23, 2026, New Horizon Health has market cap of $816M and EV of $816M.

New Horizon Health has a P/E ratio of (69.7x).

Last FY202620272028
EV/Revenue7.2x
EV/EBITDA(120.2x)
EV/EBIT(34.6x)
EV/Gross Profit8.6x
P/E(69.7x)
EV/FCF(11.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified New Horizon Health Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

New Horizon Health Margins & Growth Rates

In the most recent fiscal year, New Horizon Health reported gross margin of 84%, EBITDA margin of (6%), and net margin of (10%).

See estimated margins and future growth rates for New Horizon Health

New Horizon Health Margins

Last FY202720282029
Gross Margin84%
EBITDA Margin(6%)
EBIT Margin(21%)
Net Margin(10%)
FCF Margin(61%)

Data powered by FactSet, Inc. and Morningstar, Inc.

New Horizon Health Operational KPIs

New Horizon Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for New Horizon Health
Last FY202620272028
Revenue per Employee$0.1M
Opex per Employee$0.1M
S&M Expenses to Revenue73%
G&A Expenses to Revenue21%
R&D Expenses to Revenue12%
Opex to Revenue105%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

New Horizon Health Competitors

New Horizon Health competitors include Novogene, Castle Biosciences, Genfit, Azenta, Veraxa Biotech, Personalis, OPKO Health, Fulgent Genetics, Eckert & Ziegler and Mirxes Holding.

Most New Horizon Health public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Novogene1.7x1.6x10.7x10.7x
Castle Biosciences1.2x1.2x9.7x17.8x
Genfit8.1x7.4x(19.2x)(90.7x)
Azenta1.2x1.2x10.6x11.3x
Veraxa Biotech20116.6x-(7.3x)-
Personalis12.5x11.8x(12.3x)(9.5x)
OPKO Health1.9x2.0x(27.6x)(8.7x)
Fulgent Genetics0.7x0.7x(24.1x)(7.6x)

This data is available for Pro users. Sign up to see all New Horizon Health competitors and their valuation data.

Start Free Trial

New Horizon Health VC Funding History

Before going public, New Horizon Health raised $137M in total equity funding, across 4 rounds.

Last private valuation of New Horizon Health was $665M, after raising $30M in July 2020 from CR-CP Life Science Fund, Qiming Venture Partners, Octagon Capital Advisors, and 4 other investors.


New Horizon Health Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-20Series ECR-CP Life Science Fund; Qiming Venture Partners; Octagon Capital Advisors; Rock Springs Capital; Lilly Asia Ventures; OrbiMed; Cormorant Asset Management$30M$665MNew Horizon Health is a Chinese cancer screening biotech company focusing on early cancer detection through non-invasive diagnostic tests. The company developed ColoClear, a colorectal cancer screening test offered as a medical service at approximately RMB 1,996 per test, along with CerviClear for cervical cancer screening. In February 2021, New Horizon Health completed a Series E funding round of $30 million led by healthcare hedge fund Rock Springs Capital, with participation from OrbiMed Asia, Lilly Asia Ventures, Cormorant Asset Management, CR-CP Life Science Fund, Octagon Capital, and Qiming Venture Partners. This Series E brought the company's total capital raised to over $160 million. At the time of this funding, New Horizon Health was valued at $665 million according to investor records. The company's ColoClear test was submitted for registration with China's NMPA in 2020, positioning the company to transition from providing tests as a medical service to commercializing them as in vitro diagnostic products.
Apr-20Series DExome Asset Management; Qiming Venture Partners; SBCVC; Omniscient$20M-New Horizon Health is a biotech firm focused on health products, having raised over $130M in investments by April 2020, ranking first among Chinese companies in funding received. Later developments include a July 2020 Series E and February 2021 IPO raising $263.39M.
May-19Series CYimei Capital; DUMAC; Acorn Pacific Ventures; Sherpa Healthcare Partners; Qiming Venture Partners; VMS Asset Management; SBCVC; Legend Capital; Majuven$67M-New Horizon Health is a Chinese medtech company focused on early cancer screening, particularly colorectal cancer detection products. The company operates in the growing China early cancer screening market, projected to RMB 19.8B by 2030 at 18.7% CAGR from 2019. The specific May 2019 round involved lead investor VMS Asset Management and others like Qiming Venture Partners, Legend Capital. Later valuations include July 2020 at $630M post-money. The company went public via IPO raising $263.39M and was later acquired. Company financials from 2020 annual report show revenue of RMB 70,567 thousand (RMB 70.6M), up from RMB 58,275 thousand (RMB 58.3M) in 2019 and RMB 18,816 thousand (RMB 18.8M) in 2018, with total assets growing to RMB 818M by 2020 but reporting deficits.
Aug-17Series BQiming Venture Partners; SBCVC; Legend Capital$20M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About New Horizon Health

When was New Horizon Health founded?New Horizon Health was founded in 2018.
Where is New Horizon Health headquartered?New Horizon Health is headquartered in China.
How many employees does New Horizon Health have?As of today, New Horizon Health has over 878 employees.
Is New Horizon Health publicly listed?Yes, New Horizon Health is a public company listed on OTCM.
What is the stock symbol of New Horizon Health?New Horizon Health trades under NHZHY ticker.
When did New Horizon Health go public?New Horizon Health went public in 2021.
Who are competitors of New Horizon Health?New Horizon Health main competitors include Novogene, Castle Biosciences, Genfit, Azenta, Veraxa Biotech, Personalis, OPKO Health, Fulgent Genetics, Eckert & Ziegler, Mirxes Holding.
What is the current market cap of New Horizon Health?New Horizon Health's current market cap is $816M.
What is the current revenue of New Horizon Health?New Horizon Health's last fiscal year revenue is $113M.
What is the current EV/Revenue multiple of New Horizon Health?Current revenue multiple of New Horizon Health is 7.2x.
Is New Horizon Health profitable?No, New Horizon Health is not profitable.
How many companies New Horizon Health has acquired to date?New Horizon Health hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies New Horizon Health has invested to date?New Horizon Health hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to New Horizon Health

Lists including New Horizon Health

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial